资源描述：
《复合辅酶联合二丁酰环磷腺苷钙治疗非ST段抬高性心肌梗死的效果观察.doc》由会员上传分享，免费在线阅读，更多相关内容在工程资料-天天文库。
1、复合辅酶联合二丁酰环磷腺昔钙治疗非ST段抬高性心肌梗死的效果观察［摘要］目的研究复合辅酶联合二丁酰环磷腺苗钙治疗非ST段抬高性心肌桢死（NSTEMI）的效果。方法选择2013年1〜12月我院住院NSTEMI患者60例，随机分成对照组和治疗组，对照组给予抗血小板、抗凝、ACEI（或ARB）、B-受体阻滞剂等常规治疗，治疗组在常规治疗上给予复合辅酶（200U,1次/d,静脉滴注）联合二丁酰坏磷腺昔钙（40mg,1次/d,静脉滴注）治疗2周。记录治疗前后肌酸激酶同工酶（CK-MB）、肌钙蛋白I（cTnl）.高敏C反应蛋白（hs-CRP）、血浆B型脑钠肽（BNP）、超声心动图（UCG）参数
2、中射血分数（LVEF）、左室舒张末期内径（LVEDD）结果,比较两组参数间的差别。结果治疗组接受复合辅酶联合二丁酰环磷腺廿钙治疗后CK-MB、cTnI>hs-CRP、BNP值明显低于对照组，差异有统计学意义（P<0.05）；两组LVEDD、LVEF比较差异有统计学意义（1X0.05）。结论复合辅酚联合二丁酰环磷腺昔钙能够最大限度保护NSTEMI患者梗死心肌细胞，改善左室收缩功能，促进心功能恢复。［关键词］复合辅酶；二丁酰坏磷腺昔钙；非ST段抬高心肌梗死；脑钠肽；左室收缩功能［中图分类号］R541［文献标识码］A［文章编号］1674-4721（2015）08（b）-0131-04Ef
3、fectobservetionofcoenzymecomplexcombinedwithcalciumdibutyryladenosinecyclophosph-ateintheIre且tmentofnon-ST-segmentelevationmyocardialinfarctionLIYong-zhengZHANGQing-fengADepartmentoftheSecondInternalMedicine，CityCentralPeople'sHospitalinZaozhuangCityofShandongProvince,Zaozhuang277100,China[Abs
4、tract]ObjectiveTostudytheeffectofcoenzymecomplexcombinedwithcalciumdibutyryladenosinecyclophosph-ateontreatingpatientswithnon~STsegmentelevationmyocardialinfarction(NSTEMI)・MethodsSixtyhospitalizedNSTEMIpatientsinourhospitalfromJanuarytoDecember2013wererandomlydividedintocontrolgroupandtreatme
5、ntgroup.Tnthecontrolgroup,conventionaltherapieslikeantiplatelet,anticoagulation,angiotensinconvertingenzymeinhibitor(ACET)(orARB),andP-receptorblocker,etc・wereprovided,whileinthetreatmentgroup,coenzymecomplex(200U,1times/d,intravenousdrip)combinedwithcalciumdibutyryladenosinecyclophosph-ate(40
6、mg,1times/d,intravenousdrip)wasadded.Thecoursesoftreatmentlasted2weeks•卩arametersineludingcreatinekinase-MB(CK-MB),troponinT(cTnl),high-sensitivityC-reactiveprotein(hs-CRP),plasmatype~Bbrainnatriureticpeptide(BNP),ultrasoniccardiogram(UCG)whichreflected1eftventricularejectionfraction(LVEF)andl
7、eftventricularend-diastolicdimension(LVEDD)beforeandaftertreatmentwererecordedandcompared.ResultsIncomparisonswiththetreatmentgroupandcontrolgroup,thevaluesofCK-MB,cTnLhs~CR卩，andBNPaftertherapyinthetreatmentgroupwasmuch1owerthanthatinth
